30 routine filings (option exercises, shares withheld for taxes, grants, gifts) are not listed here. Show them
Insider buying
Bought outside the usual windowTraded Jan 30 · filed 3 days later
Since the trade −71.2% · S&P 500 −0.3% · to Nov 20
Bought 80% below the 52-week high, RSI 44, 45% under its 200-day average, 46 points behind the S&P 500 over 3 months
The CFO of Aprea Therapeutics paid $5.1K out of pocket for Aprea Therapeutics shares. 1 other person at Aprea Therapeutics bought some too, in the same month. Shares held went up 21% with this purchase.
Insider buying
Bought outside the usual windowTraded Jan 30 · filed 3 days later
Since the trade −71.2% · S&P 500 −0.3% · to Nov 20
Bought 80% below the 52-week high, RSI 44, 45% under its 200-day average, 46 points behind the S&P 500 over 3 months
Insider buying
Traded Dec 10, 2025 · filed 1 day later
Since the trade −74.9% · S&P 500 +0.3% · to Nov 20
Bought at the 52-week low, RSI 28, 45% under its 200-day average, 46 points behind the S&P 500 over 3 months
The CFO of Aprea Therapeutics paid $5.8K out of pocket for Aprea Therapeutics shares. 1 other person at Aprea Therapeutics bought some too, in the same month. Shares held went up 22% with this purchase.
Insider buying
Traded Dec 10, 2025 · filed 1 day later
Since the trade −74.9% · S&P 500 +0.3% · to Nov 20
Bought at the 52-week low, RSI 28, 45% under its 200-day average, 46 points behind the S&P 500 over 3 months
An Aprea Therapeutics director paid $25K out of pocket for Aprea Therapeutics shares. 1 other person at Aprea Therapeutics bought some too, in the same month. Shares held went up 9% with this purchase.
Traded Apr 3, 2025 · largest single transaction ~$5.6K
Insider selling
Traded Oct 18, 2024 · filed 7 days laterNot reported under a pre-arranged trading plan
Since the trade −94.8% · S&P 500 +18.0% · to Nov 20
An Aprea Therapeutics director sold $30K of Aprea Therapeutics shares. The filing does not indicate a pre-arranged trading plan.
Insider buying
Traded Oct 23, 2024 · filed 1 day later
Since the trade −94.1% · S&P 500 +19.4% · to Nov 20
The CEO of Aprea Therapeutics paid $2K out of pocket for Aprea Therapeutics shares. 3 other people at Aprea Therapeutics bought some too, in the same month.
Insider buying
Traded Oct 16, 2024 · filed 1 day later
Since the trade −93.5% · S&P 500 +18.5% · to Nov 20
An Aprea Therapeutics director paid $132K out of pocket for Aprea Therapeutics shares. 3 other people at Aprea Therapeutics bought some too, in the same month. Shares held went up 14% with this purchase.
Insider buying
Traded Oct 15, 2024 · filed 1 day later
Since the trade −92.5% · S&P 500 +19.0% · to Nov 20
The CEO of Aprea Therapeutics paid $725 out of pocket for Aprea Therapeutics shares. 3 other people at Aprea Therapeutics bought some too, in the same month.
Insider buying
Traded Oct 11, 2024 · filed 5 days later
Since the trade −91.2% · S&P 500 +19.0% · to Nov 20
The CFO of Aprea Therapeutics paid $123 out of pocket for Aprea Therapeutics shares. 3 other people at Aprea Therapeutics bought some too, in the same month.
Insider buying
Traded Oct 14, 2024 · filed 2 days later
Since the trade −91.0% · S&P 500 +18.1% · to Nov 20
An Aprea Therapeutics director paid $490 out of pocket for Aprea Therapeutics shares. 3 other people at Aprea Therapeutics bought some too, in the same month. It was the first purchase in over a year.
Insider buying
Traded Oct 11, 2024 · filed 4 days later
Since the trade −91.2% · S&P 500 +19.0% · to Nov 20
An Aprea Therapeutics director paid $27K out of pocket for Aprea Therapeutics shares. 3 other people at Aprea Therapeutics bought some too, in the same month. It was the first purchase in over a year.
Insider buying
Traded Oct 10, 2024 · filed 5 days later
Since the trade −91.0% · S&P 500 +19.7% · to Nov 20
The CFO of Aprea Therapeutics paid $1.2K out of pocket for Aprea Therapeutics shares. 3 other people at Aprea Therapeutics bought some too, in the same month. It was the first purchase in over a year.
Traded Oct 10 – Oct 14, 2024 · largest single transaction ~$2.6K